Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Choosing the wrong investments can cause you to fall behind, which is why we started StockStory - to separate the winners from the losers. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need.

Two Stocks to Sell:

B&G Foods (BGS)

Rolling One-Year Beta: -0.21

Started as a small grocery store in New York City, B&G Foods (NYSE: BGS) is an American packaged foods company with a diverse portfolio of more than 50 brands.

Why Is BGS Risky?

1. Annual sales declines of 3.3% for the past three years show its products struggled to connect with the market
2. Sales were less profitable over the last three years as its earnings per share fell by 30.8% annually, worse than its revenue declines
3. 7× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings

B&G Foods’s stock price of $4.46 implies a valuation ratio of 6.3x forward P/E. If you’re considering BGS for your portfolio, see our FREE research report to learn more.

Dole (DOLE)

Rolling One-Year Beta: 0.40

Known for its delicious pineapples and Hawaiian roots, Dole (NYSE: DOLE) is a global agricultural company specializing in fresh fruits and vegetables.

Why Do We Think DOLE Will Underperform?

1. Annual sales declines of 2% for the past three years show its products struggled to connect with the market
2. Estimated sales growth of 1.9% for the next 12 months is soft and implies weaker demand
3. Easily substituted products (and therefore stiff competition) result in an inferior gross margin of 8.4% that must be offset through higher volumes

Dole is trading at $13.79 per share, or 10x forward P/E. Dive into our free research report to see why there are better opportunities than DOLE.

One Stock to Watch:

Boston Scientific (BSX)

Rolling One-Year Beta: 0.84

Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.

Why Is BSX Interesting?

1. Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 14.9% over the past two years
2. Forecasted revenue growth of 14.4% for the next 12 months indicates its momentum over the last two years is sustainable
3. Additional sales over the last five years increased its profitability as the 12.2% annual growth in its earnings per share outpaced its revenue

At $106.50 per share, Boston Scientific trades at 36.2x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today